Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study-Reference-Cited by-同舟云学术

Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study

Published:2024-07 Issue:7 Volume:6 Page:e438-e446
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Kearsley-Fleet Lianne,Baildam Eileen,Beresford Michael W,Douglas Sharon,Foster Helen E,Southwood Taunton R,Hyrich Kimme L

Funder

British Society for Rheumatology

Versus Arthritis

Publisher

Elsevier BV

Reference28 articles.

1. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): analysis from the UK Childhood Arthritis Prospective Study (CAPS);Davies;Semin Arthritis Rheum,2016

2. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy;Emery;Ann Rheum Dis,2017

3. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis;Emery;Rheumatology (Oxford),2017

4. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study;Girolomoni;Br J Dermatol,2018

5. Clinical trial development for biosimilars;Alten;Semin Arthritis Rheum,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilars in childhood chronic rheumatic diseases: friend or foe?;The Lancet Rheumatology;2024-07